Wilmington Savings Fund Society FSB Has $1.09 Million Position in argenx SE (NASDAQ:ARGX)

Wilmington Savings Fund Society FSB raised its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 47.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,776 shares of the company's stock after acquiring an additional 574 shares during the quarter. Wilmington Savings Fund Society FSB's holdings in argenx were worth $1,092,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC lifted its holdings in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after buying an additional 21 shares during the last quarter. Choreo LLC lifted its holdings in shares of argenx by 4.4% during the 4th quarter. Choreo LLC now owns 551 shares of the company's stock valued at $342,000 after buying an additional 23 shares during the last quarter. Raymond James Trust N.A. lifted its holdings in shares of argenx by 6.0% during the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company's stock valued at $268,000 after buying an additional 28 shares during the last quarter. Hantz Financial Services Inc. lifted its holdings in shares of argenx by 8.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company's stock valued at $286,000 after buying an additional 43 shares during the last quarter. Finally, Aaron Wealth Advisors LLC lifted its holdings in shares of argenx by 10.1% during the 4th quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company's stock valued at $301,000 after buying an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ARGX shares. Citigroup lifted their price target on argenx from $512.00 to $635.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Evercore ISI boosted their target price on argenx from $675.00 to $706.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. Truist Financial restated a "buy" rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. HC Wainwright restated a "buy" rating and issued a $717.00 target price (up from $670.00) on shares of argenx in a report on Tuesday, January 14th. Finally, Piper Sandler boosted their target price on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, argenx currently has a consensus rating of "Moderate Buy" and an average target price of $658.39.

argenx Price Performance

Shares of ARGX traded down $11.93 on Friday, reaching $639.41. 266,806 shares of the stock traded hands, compared to its average volume of 265,453. The firm has a market cap of $38.85 billion, a price-to-earnings ratio of -726.60 and a beta of 0.58. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21. The stock's 50-day moving average price is $639.59 and its 200-day moving average price is $581.81.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.